Soleno Therapeutics (SLNO) Assets Average (2014 - 2026)

Soleno Therapeutics (SLNO) has 13 years of Assets Average data on file, last reported at $586.1 million in Q1 2026.

• On a quarterly basis, Assets Average rose 80.6% year-over-year to $586.1 million in Q1 2026; TTM through Mar 2026 was $586.1 million, a 80.6% increase from a year earlier, with the FY2025 full-year figure at $447.4 million, up 74.88% from the prior year.
• Assets Average for Q1 2026 stood at $586.1 million, up from $581.9 million in the prior quarter.
• Over the last five years, Assets Average for SLNO reached as high as $586.1 million in Q1 2026 and fell as low as $23.0 million in Q1 2023.
• Historically, Assets Average has averaged $215.8 million across 5 years, with a median of $174.8 million in 2024.
• Across the five-year window, Assets Average plunged 41.06% in 2023 and soared 836.96% in 2024, its largest moves.
• Year by year, Assets Average stood at $29.2 million in 2022, then soared by 317.67% to $122.1 million in 2023, then surged by 156.99% to $313.8 million in 2024, then surged by 85.4% to $581.9 million in 2025, then increased by 0.73% to $586.1 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $586.1 million in Q1 2026, $581.9 million in Q4 2025, and $466.1 million in Q3 2025.